This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| KaloBios Pharmaceuticals | |
|---|---|
| Name | KaloBios Pharmaceuticals |
| Type | Public (formerly) |
| Industry | Biotechnology |
| Founded | 2009 |
| Fate | Bankruptcy, acquisition |
| Headquarters | Hayward, California |
| Key people | Martin Shkreli; Laurence R. Schlossman |
| Products | Therapeutics (experimental) |
KaloBios Pharmaceuticals was an American biotechnology company focused on developing monoclonal antibodies and biologics for infectious diseases and oncology. Founded in 2009 with operations in Hayward, California, the company became notable for its pipeline ambitions, leadership changes, financial turbulence, and legal controversies. Its trajectory intersected with figures and institutions across the pharmaceutical industry and capital markets.
KaloBios Pharmaceuticals emerged in the aftermath of the 2008 financial crisis alongside firms such as Amgen, Genentech, Biogen, Gilead Sciences and Pfizer as part of a wave of smaller biotechnology ventures. Early governance involved executives with backgrounds connected to Novartis, GlaxoSmithKline, Eli Lilly and Company, and Sanofi. The company pursued antibody programs similar to those developed by Regeneron Pharmaceuticals and Genmab and engaged in collaborations reminiscent of agreements between Merck & Co. and academic centers such as Harvard Medical School and Johns Hopkins University. In the mid‑2010s, KaloBios attracted public attention when it was affected by high‑profile activist investors in a fashion parallel to episodes involving Valeant Pharmaceuticals International and Pershing Square Capital Management.
Corporate control of KaloBios Pharmaceuticals shifted through venture capital firms, institutional investors, and activist stakeholders comparable to holdings by BlackRock, Vanguard Group, and Goldman Sachs. Leadership transitions echoed challenges seen at companies like Theranos and board disputes reminiscent of Yahoo! governance fights. At one point, CEO appointments drew scrutiny similar to cases involving Martin Shkreli and executives previously associated with Turing Pharmaceuticals and Valeant Pharmaceuticals International. Ownership dynamics involved filings with the U.S. Securities and Exchange Commission, interactions with the NASDAQ marketplace, and corporate restructuring influenced by bankruptcy precedents such as Lehman Brothers and reorganizations like those of Mylan.
KaloBios focused on monoclonal antibody discovery and biologics manufacturing comparable to R&D programs at Roche and AstraZeneca. Its scientific teams collaborated with academic laboratories akin to partnerships between Stanford University and Massachusetts Institute of Technology while seeking to navigate regulatory pathways similar to those administered by the U.S. Food and Drug Administration and the European Medicines Agency. Preclinical work involved models and technologies paralleling efforts at Cold Spring Harbor Laboratory and Broad Institute, and pipeline strategy reflected trends set by companies such as Vertex Pharmaceuticals and Alexion Pharmaceuticals.
The company advanced candidates for infectious disease and oncology indications in the manner of investigational programs from Amgen and Bristol-Myers Squibb. Pipeline communications referenced clinical trial designs analogous to those registered with ClinicalTrials.gov and outcomes compared to therapeutic classes developed by Regeneron Pharmaceuticals and Sanofi. Partnerships and licensing negotiations were structured in ways familiar from deals negotiated by Johnson & Johnson and Bayer, with emphasis on antibody platforms similar to those commercialized by Genentech and Biogen.
KaloBios became entwined in high‑profile controversies associated with market manipulation and executive conduct issues resembling public episodes involving Martin Shkreli, Valeant Pharmaceuticals International, and legal actions pursued by the U.S. Department of Justice. Litigation touched on securities litigation trends seen in cases against companies like Enron and Theranos, and inquiries involved regulatory authorities analogous to the U.S. Securities and Exchange Commission and state attorney generals. Controversies generated media coverage in outlets comparable to The New York Times, The Wall Street Journal, and Financial Times and prompted scrutiny from investor advocacy groups similar to Public Citizen.
Financial trajectories mirrored those of many small cap biotechnology firms facing high cash burn, financing rounds, and market volatility akin to Moderna in its early stages or Allergan in restructuring periods. KaloBios experienced stock price fluctuations on exchanges such as the NASDAQ and engaged in fundraising activities resembling convertible notes and equity offerings used by peers like Celgene and Bluebird Bio. Accounting and audit processes followed standards set by the Public Company Accounting Oversight Board and filings referenced regulatory frameworks administered by the U.S. Securities and Exchange Commission.
The company’s legacy reflects debates at the intersection of biotech innovation, corporate governance, and market conduct similar to broader discussions sparked by Theranos, Martin Shkreli, and Valeant Pharmaceuticals International. Lessons drawn from its rise and fall have been cited in analyses by policy institutes comparable to the Brookings Institution and Kaiser Family Foundation and used as case studies in business schools such as Harvard Business School and Wharton School. Its story informed conversations about investor activism, regulatory oversight, and ethical leadership in biopharmaceutical development alongside enduring examples from Amgen, Genentech, and Gilead Sciences.
Category:Defunct biotechnology companies of the United States